Chronic Lymphocytic Leukemia Podcasts This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Higher-Dose Ivermectin for Outpatients With COVID-19, Trends in Cardiovascular Risk Factor Prevalence and Control in US Adults, Review of Chronic Lymphocytic Leukemia, and more
Editor's Summary by Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of JAMA, the Journal of the American Medical Association, for the March 21, 2023 issue. (Source: JAMA: This Week's Audio Commentary)
Source: JAMA: This Week's Audio Commentary - March 21, 2023 Category: General Medicine Authors: JAMA Network Source Type: podcasts

ASH 2016 Page 3 Maintenance Therapy in Chronic Lymphocytic Leukemia
Author: cancergrace Added: 06/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2019 Category: Cancer & Oncology Source Type: podcasts

ASH 2016 Page 2 Update on New Chronic Lymphocytic Leukemia Drugs
Author: cancergrace Added: 06/28/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2019 Category: Cancer & Oncology Source Type: podcasts

CLL14 Trial Outcomes
Lori A. Leslie, MD, Hematologist-Oncologist, Lymphoma Department, John Theurer Cancer Center, Hackensack Meridian Health shares details on the CLL14 trial in chronic lymphocytic leukemia (CLL) that wa... Author: obr Added: 06/27/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Should all HL patients be treated the same
Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Should all HL patients be treated the same Author: cancergrace Added: 06/26/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2019 Category: Cancer & Oncology Source Type: podcasts

CLL-14 Data Trial in Chronic Lymphocytic Leukemia
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute discusses the data found in the recent CLL-14 study in chronic lymphocytic leukemia (CLL). Author: obr Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts

Opinion on Ibrutinib on 1st Line CLL
Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL). Author: obr Added: 06/25/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 25, 2019 Category: Cancer & Oncology Source Type: podcasts

Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and c
 Rod Humerickhouse discusses the Phase 3 CLL14 Trial. Background: The multinational, open-label, phase 3 CLL14 trial compared fixed-duration targeted VenG treatment with chlorambucil-obinutuzumab ... Author: Annual-Meeting Added: 06/07/2019 (Source: Oncology Tube)
Source: Oncology Tube - June 7, 2019 Category: Cancer & Oncology Source Type: podcasts

Mollie Moran, APRN-CNP, AOCNP - Taking Aim at B-Cell Malignancies With BTK Inhibitors: Oncology Nurse Perspectives and Insights on Clinical Care
Go online to PeerView.com/XAC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium held during the Oncology Nursing Society’s (ONS) 44th Annual Congress, a panel of expert nurse faculty use a MasterClass/case-forum design to offer an in-depth review of BTK inhibitors, their therapeutic applications in B-cell malignancies, and the core nurse-focused practice issues that are central to the further integration of BTK inhibitors into treatment plans for patients with cancers such as chronic lymphocytic leukemia (CLL) and mant...
Source: PeerView CME/CE Audio Podcast - Pulmonology - May 27, 2019 Category: Respiratory Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Key Insights in Chronic Lymphocytic Leukemia: from Lymphoma & Myeloma 2018
Earn CME: <a target='_blank' href='https://naccme.com/program/7308'>https://naccme.com/program/...</a> In this Key Insights activity, Drs. Morton Coleman and Richard R. Furman discuss CLL-related highlights from Lymphoma & Myeloma 2018: An International Con... Author: imedex Added: 11/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - November 7, 2018 Category: Cancer & Oncology Source Type: podcasts

iFCG yields unprecedented MRD negativity in CLL
FCR chemoimmunotherapy is most effective in the IGVH mutated, non-17p deletion chronic lymphocytic leukemia (CLL) patient subgroup. With the advent of novel drugs in the field however, Nitin Jain, MD,... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

CAR T-cells in CLL: the current landscape
While CAR T-cells are an approved therapy option in acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), the research in chronic lymphocytic leukemia (CLL) is somewhat behind.... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel approaches to first line CLL treatment
First line therapies for chronic lymphocytic leukemia (CLL) have developed beyond the historic approach of giving all patients FCR chemoimmunotherapy. In this video, recorded at the 2018 Society of He... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Venetoclax combinations effective in elderly AML
While venetoclax is widely used in chronic lymphocytic leukemia (CLL) to good effect, previous studies have suggested that the drug does not yield such good results in acute myeloid leukemia (AML). In... Author: VJHemOnc Added: 09/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 21, 2018 Category: Cancer & Oncology Source Type: podcasts

Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for the treatment of refractory chronic lymphocytic Leukemia (CLL). A key... Author: VJHemOnc Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts